hs-20093 + epirubicin

HS-20093 + epirubicin is a **combination drug regimen** being studied for the treatment of advanced bone and soft tissue sarcoma. HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) targeting B7-H3—a protein highly expressed on certain sarcomas and other solid tumors. It consists of an anti-B7-H3 monoclonal antibody linked to a topoisomerase inhibitor payload. Its mechanism involves targeting and binding to B7-H3 on tumor cells, delivering the cytotoxic payload intracellularly to induce cell death. Epirubicin is an anthracycline chemotherapy agent acting via DNA intercalation and topoisomerase II inhibition, leading to apoptosis of rapidly dividing tumor cells. The combination aims to synergize the B7-H3 targeting ADC's selectivity and cytotoxicity with standard chemotherapy to improve anti-tumor efficacy in patients who have progressed on or are intolerant to standard therapies[1][3][4][7].